HighTower Advisors’s Provention Bio PRVB Stock Holding History
Bought
Maintained
Sold
Other funds holding PRVB
HighTower Advisors's PRVB Position: Q1 2023 in Review
HighTower Advisors sold out of Provention Bio (PRVB) in Q1 2023, closing a stake of 25,820 shares — an estimated $273K sold.
HighTower Advisors first reported a position in PRVB in Q3 2018 and held it in 8 quarters. The position peaked at $273K in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.
- HighTower Advisors reported no remaining Provention Bio position as of Q1 2023 after selling out during the quarter.
- HighTower Advisors sold 25,820 Provention Bio shares in Q1 2023, an estimated $273K.
- HighTower Advisors first reported a position in Provention Bio in Q3 2018 and held it in 8 quarters.
- HighTower Advisors's Provention Bio position peaked at $273K in Q4 2022.
- 182 funds tracked by Wall St. Rank held Provention Bio as of Q1 2023.
Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.